Like all other human malignancies, prostate cancer cells escape apoptotic death through highly efficient pathways involving multiple mechanisms [6, 7]. X-linked inhibitor of apoptosis protein-associated factor-1 (XAF1) was first identified as an interacting protein of X-linked inhibitor of apoptosis (XIAP) [8]. XIAP suppresses apoptotic cell death by binding to caspases and inhibiting their functions. XAF1 antagonizes XIAP activities, thereby promoting apoptosis [9]. XAF1 can dramatically sensitize cancer cells to apoptotic triggers

such as TRAIL, etoposide treatments 5-fluorouracil [10], H2O2, c-irradiation, ultraviolet [11], and tumour necrosis factor-α, which are independent of its interaction with XIAP [12]. XAF1 is therefore believed to play an important role in the major apoptosis-related pathways. XAF1 also serves as a candidate tumour suppressor gene. Loss of XAF1 has been observed in a variety BIX 1294 ic50 of cancer cell

lines and human cancers [13–16]. However, little is yet known about its potential selleck inhibitor implication in prostate cancer. So far, there have been no effective therapeutic measures for the treatment of hormone refractory prostate cancer. Treatment with somatostatin may therefore be a possible therapeutic alternative to chemotherapy in hormone refractory prostate cancer patients. Somatostatin, originally identified as a neuropeptide inhibiting growth hormone release more than 30 years ago, is widely present in central and peripheral human cells/tissues including prostate. Somatostatin has been shown to exert a potent anti-tumour action by affecting tumour cell proliferation, apoptosis, angiogenesis and the host’s immune response [17–21]. Octreotide is an analogue of somatostatin and has been used in clinical practice since data emerged in the 1980 s confirming its ability to palliate carcinoid syndrome

[22]. Our previous results have shown that somatostatin may affect the mitochondria Oxaprozin of LNCaP and DU145 cells in a way that eventually triggers mitochondrial-mediated apoptosis and exert its effects on prostate cancer cells via MAPK pathway and by regulating the activities of phosphotyrosine phosphatases [23]. In the current study, we examined XAF1 mRNA and protein expression in four cell lines, and determined regulatory effects of somatostatin and Octreotide on XAF1 expression in prostate cancer cell lines. We found that somatostatin and Octreotide up-regulated XAF1 mRNA and protein expression in prostate cancer cell lines. The enhanced XAF1 expression by somatostatin indicates a promising strategy for prostate cancer therapy. Materials and methods Cell lines and cell culture A human prostate epithelial cell line (RWPE-1) and prostate cancer cell lines (LNCaP, DU145 and PC3) were used and were obtained from the American Type Culture Collection (ATCC). LNCaP, DU145 and PC3 were maintained in RPMI-1640 medium supplemented with 10% foetal bovine serum (FBS).